Search results
Results From The WOW.Com Content Network
B-cell activating factor (BAFF) B-cell cancers Tacatuzumab tetraxetan: AFP-Cide: mab: humanized: alpha-fetoprotein: cancer Tadocizumab [103] Fab: humanized: integrin α IIb β 3: percutaneous coronary intervention: Tafasitamab [47] Monjuvi: mab: humanized (from mouse) CD19: Y: relapsed or refractory diffuse large B-cell lymphoma Talacotuzumab ...
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). [5] [6]Tagraxofusp is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin.
Mirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it. [3] The inhibition to the mutation has shown to shrink the size of its tumors. [4] The company is based in San Diego, California. [5] The company’s name comes from the Italian word for “targeted” (Mirati).
The Poisons Standard organises substances into 10 schedules (and unscheduled substances), [10] therapeutic goods are generally organised only into schedules 2, 3, 4 and 8: unscheduled substances: unscheduled substances are available for purchase at any retailer. schedule 1 (S1) - Blank: this schedule is left intentionally blank.
Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. [1]
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. [11]
Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings.
BOLD-100, or sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)], is a ruthenium-based anti-cancer therapeutic in clinical development.As of February 2024, BOLD-100 was being tested in a Phase 1b/2a clinical trial in 117 patients with advanced gastrointestinal cancers in combination with the chemotherapy regimen FOLFOX. [1]